Literature DB >> 7792126

Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group.

M Klein1.   

Abstract

Acute lower respiratory tract infections in children are a worldwide public health problem, with an estimated 4 million potentially preventable deaths every year. Until recently, penicillin and related drugs were the treatment of choice for empiric therapy of paediatric lower respiratory tract infections. However, concerns over the emergence of penicillin-resistant strains of Streptococcus pneumoniae and beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis have led physicians to turn increasingly towards alternatives, such as the third generation cephalosporins. The oral extended spectrum cephalosporin cefpodoxime proxetil is highly active against the bacterial pathogens commonly associated with childhood lower respiratory tract infections. In order to evaluate its clinical efficacy in children with acute febrile lower respiratory tract infections, an international, multicenter, comparative, randomized open study was conducted in children ages 3 months to 11.5 years. Of 348 cases enrolled, 234 were randomized to cefpodoxime proxetil (8 mg/kg/day twice daily) and 114 to amoxicilin/clavanulate (amoxicillin 40 mg/kg/day 3 times a day). The duration of treatment was 10 days. Pretreatment diagnosis was pneumonia in 292 patients, bronchiolitis in 19 patients and acute bronchitis in 37 patients. Pathogens isolated from 59 cases included H. influenzae (47.5%), S. pneumoniae (23.7%), M. catarrhalis (11.9%) and Haemophilus parainfluenzae (6.8%). Clinical efficacy was evaluable in 278 children at the end of treatment when 95.2% of patients in the cefpodoxime proxetil group and 96.7% of patients in the amoxicillin/clavanulate group showed a satisfactory clinical response (cured or improved). The improvement was sustained at the follow-up visit, 10 to 20 days after completion of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7792126     DOI: 10.1097/00006454-199504001-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood.

Authors: 
Journal:  Thorax       Date:  2002-05       Impact factor: 9.139

Review 2.  Oral antibiotics versus parenteral antibiotics for severe pneumonia in children.

Authors:  M X Rojas; C Granados
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 3.  Antimicrobial Therapy in Community-Acquired Pneumonia in Children.

Authors:  Samriti Gupta; Rakesh Lodha; S K Kabra
Journal:  Curr Infect Dis Rep       Date:  2018-09-20       Impact factor: 3.725

Review 4.  Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.

Authors:  J A Balfour; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

5.  The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia.

Authors:  Eran Lavi; Oded Breuer
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

Review 6.  Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.

Authors:  B Fulton; C M Perry
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  Comparative evaluation of cefpodoxime versus cefixime in children with lower respiratory tract infections.

Authors:  Jayati Sengupta; A K Mondal; Piyush Jain; R D Garg; N C Mathur; A K Moharana
Journal:  Indian J Pediatr       Date:  2004-06       Impact factor: 1.967

Review 8.  Antibiotics for community-acquired pneumonia in children.

Authors:  Rakesh Lodha; Sushil K Kabra; Ravindra M Pandey
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

Review 9.  Cefpodoxime - utility in respiratory tract infections and typhoid fever.

Authors:  Anju Aggarwal; Suman Rath
Journal:  Indian J Pediatr       Date:  2004-05       Impact factor: 1.967

10.  Predicting Oral Beta-lactam susceptibilities against Streptococcus pneumoniae.

Authors:  Mark E Murphy; Eleanor Powell; Joshua Courter; Joel E Mortensen
Journal:  BMC Infect Dis       Date:  2021-07-13       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.